Thomas Blevins

Summary

Publications

  1. doi request reprint DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac Expressway, Building 3, Suite 200, Austin, Texas 78731, USA
    J Clin Endocrinol Metab 96:1301-10. 2011
  2. doi request reprint Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac, Austin, TX 78731, USA
    Postgrad Med 122:172-83. 2010
  3. pmc Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX, USA
    Diabetes Ther 7:361-8. 2016
  4. doi request reprint Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin
    Thomas Blevins
    Texas Diabetes and Endocrinology, P A, 6500 N MoPac Expwy, Building III, Suite 200, Austin, TX 78731, USA 1 512 458 8400
    Expert Opin Drug Saf 14:789-93. 2015
  5. doi request reprint Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 125:191-204. 2013
  6. pmc Professional continuous glucose monitoring in clinical practice 2010
    Thomas C Blevins
    Texas Diabetes and Endocrinology, Austin, Texas 78731, USA
    J Diabetes Sci Technol 4:440-56. 2010
  7. doi request reprint Control of postprandial glucose levels with insulin in type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 123:135-47. 2011
  8. doi request reprint Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, P A, Austin, TX, USA
    Postgrad Med 122:118-28. 2010

Collaborators

Detail Information

Publications8

  1. doi request reprint DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac Expressway, Building 3, Suite 200, Austin, Texas 78731, USA
    J Clin Endocrinol Metab 96:1301-10. 2011
    ..We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes...
  2. doi request reprint Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac, Austin, TX 78731, USA
    Postgrad Med 122:172-83. 2010
    ..The DPP-4 inhibitors effectively lower glucose and are weight neutral...
  3. pmc Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX, USA
    Diabetes Ther 7:361-8. 2016
    ..This post hoc analysis examined the timing to onset of clinical responses and their correlations with exenatide concentrations after initiation of exenatide QW in patients with T2D...
  4. doi request reprint Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin
    Thomas Blevins
    Texas Diabetes and Endocrinology, P A, 6500 N MoPac Expwy, Building III, Suite 200, Austin, TX 78731, USA 1 512 458 8400
    Expert Opin Drug Saf 14:789-93. 2015
    ..Empagliflozin is an SGLT2 inhibitor that has been demonstrated to significantly reduce blood glucose levels and is well tolerated in patients with T2DM...
  5. doi request reprint Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 125:191-204. 2013
    ..This review outlines the benefits of SMBG in the management of patients with T2DM not treated with insulin, and highlights strategies for improving the effectiveness of SMBG-based treatment interventions in this population...
  6. pmc Professional continuous glucose monitoring in clinical practice 2010
    Thomas C Blevins
    Texas Diabetes and Endocrinology, Austin, Texas 78731, USA
    J Diabetes Sci Technol 4:440-56. 2010
    ..Developing a PCGM program at a medical office involves understanding reimbursement issues and having trained staff and a process in place to initiate the test and download and interpret the data...
  7. doi request reprint Control of postprandial glucose levels with insulin in type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 123:135-47. 2011
    ..Postprandial glucose is an important glycemic burden in many patients; routine targeting and regular monitoring has potential to ameliorate the cardiovascular complications of T2DM...
  8. doi request reprint Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, P A, Austin, TX, USA
    Postgrad Med 122:118-28. 2010
    ..The objective was to compare the treatment effects between exenatide and insulin, which are 2 injectable peptide hormone-based therapy options for the treatment of type 2 diabetes mellitus...